We believe Mr. Underhill’s experience helping MP3.com to the top will strengthen and power our public market position as we prepare ourselves for an IPO. Rod’s entrepreneurial spirit and broad ranging expertise in navigating difficult waters is a tremendous asset to the firm.
Sacramento, CA (PRWEB) January 5, 2006
Telomolecular Corp. announces that lawyer, best-selling author, technology law professor and cofounder of MP3.com, Mr. Rod Underhil, has joined the Telomolecular team as General Counsel. MP3.com’s market value touched $6.9 billion on the day of its IPO.
“Telemolecular is poised to make stunning advancements in medical technology previously unseen in our lifetime,” said Underhill. “It is my belief that Telemolecular may well develop new therapies that prove to be as revolutionary as the Salk Vaccine and antibiotics were when they were first introduced. I am pleased to join the Telemolecular team as we look forward to taking further steps towards the day when we can announce significant medical breakthroughs based on Telemolecular technologies and science.”
According to Telomolecular CEO Matthew A. Sarad, “We believe Mr. Underhill’s experience helping MP3.com to the top will strengthen and power our public market position as we prepare ourselves for an IPO. Rod’s entrepreneurial spirit and broad ranging expertise in navigating difficult waters is a tremendous asset to the firm.”
Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. The Corporation intends to finance research and development, and commercialize products. By combining new large-molecule delivery technologies with new protein discoveries it may be possible to lengthen chromosomal telomeres in therapeutic ways. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs we recognize as human aging.
Telomolecular Investor Relations
Mr. Jeremy Jobe
# # #